Scientific and industrial challenges of developing nanoparticle-based theranostics and multiple-modality contrast agents for clinical application

Abstract

To select the best nanoparticle candidate for clinical translation, several key-issues must be considered early, both at the research (left) and marketing (right) levels. The radar graph may serve an evaluation tool. The weighing of the individual criterion is crucial.